Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3374849 · 1 trial · 1 indication
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY3374849 - SC (Part A) | EXPERIMENTAL | Single subcutaneous (SC) dose of LY3374849 |
| Insulin Degludec - SC (Part A) | EXPERIMENTAL | Single SC dose of insulin degludec |
| LY3374849 - SC (Part B) | EXPERIMENTAL | Single dose of LY3374849 administered SC in up to three of three study periods |
| LY3374849 - IV (Part B) | EXPERIMENTAL | Single dose of LY3374849 administered intravenously (IV) in up to one of three study periods |
| LY3374849 - IV (Part C) | EXPERIMENTAL | Single IV dose of LY3374849 in one of two study periods |
| Insulin Degludec - IV (Part C) | EXPERIMENTAL | Single IV dose of insulin degludec in one of two study periods |
| Name | Type | Description |
|---|---|---|
| LY3374849 - SC | DRUG | Administered SC |
| Insulin Degludec - SC | DRUG | Administered SC |
| LY3374849 - IV | DRUG | Administered IV |
| Insulin Degludec - IV | DRUG | Administered IV |
Inclusion Criteria: * Healthy male or a female who cannot become pregnant * Have a body mass index (BMI) of at least 18 kilogram per square meter (kg/m²) * Have normal blood pressure, pulse rate, electrocardiogram (ECG), blood and urine laboratory test results that are acceptable for the study * Ha...
LY3374849 is an investigational small molecule being developed by Eli Lilly and Company. It is currently in Phase 1 clinical development. The drug has been studied in healthy participants, with one completed trial involving 89 individuals.
LY3374849 is being studied for use in healthy participants. It is an investigational drug in Phase 1 clinical development, meaning it is being evaluated for safety and tolerability in humans. Its intended therapeutic use has not been established yet.
LY3374849 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the stock exchange under the ticker symbol LLY. The company is conducting clinical trials to evaluate this investigational small molecule drug.
LY3374849 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug is being studied in healthy participants to assess its safety and tolerability.
LY3374849 has been studied in one clinical trial, identified as NCT03726125, titled "A Study of LY3374849 in Healthy Participants." This Phase 1 trial was completed and enrolled 89 participants in Singapore. The trial was randomized, double-blind, and controlled.